Use and misuse of the P-value

Bulletin of the NYU Hospital for Joint Diseases

Volumn 66, Issue 2, 2008, Pages 146-149

  Lesaffre, Emmanuel ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CONFERENCE PAPER; CONFIDENCE INTERVAL; METHODOLOGY; OSTEOARTHRITIS; SAMPLE SIZE; STATISTICAL ANALYSIS;

BIOMEDICAL RESEARCH; CYCLOOXYGENASE INHIBITORS; HUMANS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PYRAZOLES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; STATISTICS AS TOPIC; SULFONAMIDES; SULFONES;

EID: 46049092595     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Bingham CO III, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology. 2007;46:496-507.
2. Lesaffre E. Superiority, equivalence and non-inferiority trials. Bull NYU Hosp Jt Dis. 2008;66(2):150-4.
3. Moyé LA. Multiple Analyses in Clinical Trials: Fundamentals for Investigators, New York: Springer-Verlag, 2003.
4. Proschan MA, Lan KKG, Wittes JT. Statistical Monitoring of Clinical Trials: A Unified Approach, New York: Springer-Verlag, 2006.